Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS-252424 is a potent and selective small molecule inhibitor of the gamma isoform of Class I phosphoinositide 3-kinase (PI3Kγ), with an IC50 of approximately 30 nM. It demonstrates high selectivity (over 30-fold) for PI3Kγ compared to the α, β, and δ isoforms. Developed as part of a series of thiazolidinedione derivatives, AS-252424 is primarily utilized as a chemical probe in preclinical research to investigate the role of PI3Kγ in inflammatory responses, immune cell trafficking, and oncology. In the context of pancreatic cancer, research has shown that AS-252424 can effectively induce apoptosis and alter global phosphorylation patterns, although its therapeutic potential may be hindered by adaptive resistance mechanisms like Akt reactivation, suggesting a need for combination strategies with other isoform-selective inhibitors.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AS-252424.